Overview

Randomized Trial of Ultrashort Psychotherapy vs Sustained-Release Bupropion for Smoking Cessation

Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
Background Smokers often reject drugs as smoking cessation aids. Nonpharmacological interventions are notoriously under-evaluated. Methods We conducted a randomized clinical trial in which we compared a medication, i.e., sustained-release bupropion (Zyban®; 413 subjects), at the time of the trial the most efficacious pharmacological smoking cessation aid, with an ultrashort psychotherapeutic intervention, Psychodynamic Model Training® (366 subjects), a manual-based psychodynamically oriented 1 ½ day autosuggestion training. Outcome criterion was 12-month self-reported continuous abstinence confirmed by urine cotinine levels below the level of detection (13 ng/ml) or, in an independent analysis, by exhaled carbon monoxide of 10 ppm or less at all interviews conducted at 3, 6, and 12 months.
Phase:
Phase 4
Details
Lead Sponsor:
Medical University Innsbruck
Treatments:
Bupropion